These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 10720971)

  • 41. Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children.
    Schmitt CP; Haraldsson B; Doetschmann R; Zimmering M; Greiner C; Böswald M; Klaus G; Passlick-Deetjen J; Schaefer F
    Kidney Int; 2002 Apr; 61(4):1527-36. PubMed ID: 11918761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypertonicity of dialysis fluid suppresses intraperitoneal inflammation.
    Wieczorowska-Tobis K; Styszynski A; Polubinska A; Radkowski M; Breborowicz A; Oreopoulos DG
    Adv Perit Dial; 2000; 16():262-6. PubMed ID: 11045307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution.
    Günal AI; Duman S; Sen S; Unsal A; Terzioğlu E; Akçiçek F; Basci A
    J Nephrol; 2001; 14(3):184-9. PubMed ID: 11439742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis.
    Peng H; Cheung AK; Reimer LG; Kamerath CD; Leypoldt JK
    Kidney Int; 2001 Jan; 59(1):44-51. PubMed ID: 11135056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?
    Duman S; Günal AI; Sen S; Asçi G; Ozkahya M; Terzioglu E; Akçiçek F; Atabay G
    Perit Dial Int; 2001; 21(2):219-24. PubMed ID: 11330572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of increased dialysate fill volume on peritoneal fluid and solute transport.
    Wang T; Heimbürger O; Cheng H; Waniewski J; Bergström J; Lindholm B
    Kidney Int; 1997 Oct; 52(4):1068-76. PubMed ID: 9328947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What does the dialysate level of matrix metalloproteinase 2 tell us?
    Ertilav M; Timur O; Hür E; Bozkurt D; Nar H; Kologlu T; Sen S; Duman S
    Adv Perit Dial; 2011; 27():6-10. PubMed ID: 22073820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
    Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
    Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
    Parikova A; Zweers MM; Struijk DG; Krediet RT
    Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiological saline is not a biocompatible peritoneal dialysis solution.
    Wang T; Heimbürger O; Qureshi AR; Waniewski J; Bergström J; Lindholm B
    Int J Artif Organs; 1999 Feb; 22(2):88-93. PubMed ID: 10212043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
    Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
    Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.
    García-López E; Pawlaczyk K; Anderstam B; Qureshi AR; Kuzlan-Pawlaczyk M; Heimbürger O; Werynski A; Lindholm B
    Perit Dial Int; 2007; 27(4):415-23. PubMed ID: 17602150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of a dialysis solution with a combination of glycerol/amino acids/dextrose on the peritoneal membrane in chronic renal failure.
    de Graaff M; Zegwaard AH; Zweers MM; Vlijm A; de Waart DR; Vandemaele F; Struijk DG; Krediet RT
    Perit Dial Int; 2010; 30(2):192-200. PubMed ID: 20124192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discriminative impact of ultrafiltration on peritoneal protein transport.
    Waniewski J; Wang T; Heimbürger O; Werynski A; Lindholm B
    Perit Dial Int; 2000; 20(1):39-46. PubMed ID: 10716582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats.
    Duman S; Sen S; Sozmen EY; Oreopoulos DG
    Int J Artif Organs; 2005 Feb; 28(2):170-6. PubMed ID: 15770605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis.
    Malik AR; Little MA; Henriksson M; Tam FW; Brown EA
    J Nephrol; 2007; 20(3):340-9. PubMed ID: 17557268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-acetylglucosamine reduces inflammatory response during acute peritonitis in uremic rats.
    Breborowicz A; Połubinska A; Wu G; Tam P; Oreopoulos DG
    Blood Purif; 2006; 24(3):274-81. PubMed ID: 16465047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
    Lee CJ; Subeq YM; Lee RP; Liou HH; Hsu BG
    Cytokine; 2014 Jan; 65(1):105-18. PubMed ID: 24210651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyaluronan influence on diffusive permeability of the peritoneum in vitro.
    Grzelak T; Szary B; Czyzewska K
    Adv Perit Dial; 2008; 24():22-6. PubMed ID: 18985996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peritoneal surface area and its permeability in rats.
    Kuzlan M; Pawlaczyk K; Wieczorowska-Tobis K; Korybalska K; Breborowicz A; Oreopoulos DG
    Perit Dial Int; 1997; 17(3):295-300. PubMed ID: 9237292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.